SCHEMBL23218235

SCHEMBL23218235

CC(C)(C)OC(=O)Cc1ccccc1OCc1cc2cc(CO)cc(I)c2o1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 5/20 0.37
MTNR1B P49286 5/20 0.37
CFD P00746 8/20 0.35
F11 P03951 3/20 0.34
TPSB2 P20231 3/20 0.34
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
KMT2A Q03164 2/20 0.31
MEN1 O00255 1/20 0.31
PLG P00747 1/20 0.31
PLAU P00749 1/20 0.31
KLKB1 P03952 1/20 0.31
F7 P08709 1/20 0.31
KDM4E B2RXH2 1/20 0.31
GAA P10253 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
RORC P51449 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853229 1.00 MTNR1A (0.37) MTNR1AMTNR1BCFDF11TPSB2
SCHEMBL23218513 0.93 MTNR1A (0.36) MTNR1AMTNR1BCFDF11TPSB2
SCHEMBL29852443 0.90 CFD (0.37) MTNR1AMTNR1BCFDF11TPSB2
SCHEMBL23218573 0.90 CFD (0.37) MTNR1AMTNR1BCFDF11TPSB2
SCHEMBL29852925 0.89 TBXAS1 (0.38) MTNR1AMTNR1BCFDF11TPSB2
SCHEMBL23219011 0.89 TBXAS1 (0.38) MTNR1AMTNR1BCFDF11TPSB2
SCHEMBL29853074 0.87 MTNR1A (0.37) MTNR1AMTNR1BCFDALDH1A1LMNA
SCHEMBL23219131 0.87 MTNR1A (0.37) MTNR1AMTNR1BCFDLMNAL3MBTL1
SCHEMBL23218702 0.87 MTNR1A (0.37) MTNR1AMTNR1BCFDALDH1A1LMNA
SCHEMBL30009876 0.87 CFD (0.35) MTNR1AMTNR1BCFDF11TPSB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB MTNR1A 3930/4885MTNR1B 3580/4885CFD 1/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB MTNR1A 3848/4885MTNR1B 2984/4885CFD 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.